Education
About Us
Working with TipRanks
Follow Us
Zoetis (ZTS)
:ZTS
ZTS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$139.70 - $200.33
Previous CloseN/A
Volume625.10K
Average Volume (3M)3.39M
Market Cap
$65.30B
Enterprise Value$74.83B
Total Cash (Recent Filing)$1.44B
Total Debt (Recent Filing)$210.00M
Price to Earnings (P/E)25.4
Beta0.60
Next Earnings
Oct 30, 2025EPS Estimate
1.64Last Dividend Ex-Date
Jul 18, 2025Dividend Yield1.31%
Share Statistics
EPS (TTM)1.76
Shares Outstanding443,183,470
10 Day Avg. Volume4,238,098
30 Day Avg. Volume3,391,179
Financial Highlights & Ratios
PEG Ratio3.88
Price to Book (P/B)15.51
Price to Sales (P/S)8.00
P/FCF Ratio32.20
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue7.97
Enterprise Value/Gross Profit11.16
Enterprise Value/Ebitda18.84
Forecast
1Y Price Target
$186.11Price Target Upside26.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Bulls Say, Bears Say
Bulls Say
Growth ProspectsThere remain a significant amount of un- and under-treated pets across parasiticides, dermatology, and OA pain, representing opportunities for incremental market growth.
Market ConfidenceRaised full-year guidance should give incremental confidence that the long-term growth algorithm is not broken.
Product PerformanceZoetis' two largest franchises, parasiticides and dermatology, continued to perform well, supported by end market demand and continued sales growth in alternative channels.
Bears Say
Competitive PressureThe potential slowdown in the second half is largely short-term from the potential for aggressive pricing/promotional tactics from new competitive entrants.
Product Launch ChallengesLibrela performance was light both domestically and internationally, with concerning dynamics popping up in English-speaking international regions.
Sales PerformanceThe continued lack of traction in the US Librela launch, combined with slippage in International sales, represents an incremental risk to the growth story.
Zoetis News
ZTS FAQ
What was Zoetis’s price range in the past 12 months?
Zoetis lowest stock price was $139.70 and its highest was $200.33 in the past 12 months.
What is Zoetis’s market cap?
Zoetis’s market cap is $65.30B.
When is Zoetis’s upcoming earnings report date?
Zoetis’s upcoming earnings report date is Oct 30, 2025 which is in 79 days.
How were Zoetis’s earnings last quarter?
Zoetis released its earnings results on Aug 05, 2025. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.621 by $0.139.
Is Zoetis overvalued?
According to Wall Street analysts Zoetis’s price is currently Undervalued.
Does Zoetis pay dividends?
Zoetis pays a Quarterly dividend of $0.5 which represents an annual dividend yield of 1.31%. See more information on Zoetis dividends here
What is Zoetis’s EPS estimate?
Zoetis’s EPS estimate is 1.64.
How many shares outstanding does Zoetis have?
Zoetis has 443,183,470 shares outstanding.
What happened to Zoetis’s price movement after its last earnings report?
Zoetis reported an EPS of $1.76 in its last earnings report, beating expectations of $1.621. Following the earnings report the stock price went down -3.748%.
Which hedge fund is a major shareholder of Zoetis?
Currently, no hedge funds are holding shares in ZTS
Zoetis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$186.11 (26.30% Upside)
$186.11 (26.30% Upside)
Blogger Sentiment
Bullish
ZTS Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 475.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 2.4%
Last 30 Days ▲ 2.4%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.79%
12-Months-Change
Fundamentals
Return on Equity
52.54%
Trailing 12-Months
Asset Growth
2.22%
Trailing 12-Months
Company Description
Zoetis
Zoetis Inc. (ZTS) is a global leader in animal health, dedicated to supporting the health and well-being of livestock and companion animals. Founded in 1952, the company develops and manufactures a wide range of veterinary medicines, vaccines, and diagnostic products. Zoetis operates in various sectors including livestock, such as cattle, swine, and poultry, as well as companion animals like dogs and cats. Its core products include parasiticides, anti-infectives, vaccines, and nutritional products, all aimed at enhancing animal health and productivity.
ZTS Company Deck
ZTS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Zoetis demonstrated strong financial performance with robust organic revenue growth across multiple segments and raised full-year guidance. However, challenges in the OA Pain market and macroeconomic concerns persist.View all ZTS earnings summariesZTS Revenue Breakdown
67.83% Companion animal
31.31% Livestock
0.86% Contract manufacturing & human health
ZTS Stock 12 Month Forecast
Average Price Target
$186.11
▲(26.30% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Phibro Animal Health
―
HUTCHMED
―
Elanco Animal Health
―
Ownership Overview
0.07% Insiders
19.85% Mutual Funds
1.60% Other Institutional Investors
56.26% Public Companies and Individual Investors